<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016083017413N16</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-09-12</date_registration>
      <primary_sponsor>Baqiyatallah University of Medical Sciences</primary_sponsor>
      <public_title>Evaluating effect of PRP-enriched gelfoam on healing of Tympanic membrane rupture</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the Effect of PRP-enriched Gelfoam and Conventional Gelfoam on the Healing of Chronic Tympanic Membrane Perforation; A Double-blind Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/16027</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>3</phase>
      <hc_freetext>Tympanic Membrane Perforation.</hc_freetext>
      <i_freetext>Intervention 1: After transferring the patient to operation room and before presence of surgeon, 8 ml of blood will be obtained from patient’s brachial vein in intervention group and will be stored in PRP kits (RegenKit BCT). Samples will be centrifuged in room’s temperature by 3000 rounds/min in 5 minutes then 3 ml of the resulting solution will be disposed from the top of the kit. Based on factory’s instruction, the remaining solution will be shaken for obtaining 1ml of high density and homogenous PRP.  In the following, small (1 and 2- mm) and two large (1 to 2 mm more than size of perforation) gel foams will be prepared and enriched with PRP in galipot. In control group gel foams will be impregnated with normal saline for blinding purpose. Then surgeon, who is not aware of added material to gel foams, will be paged to the OR. After convenient prep and drep 1 ml of Lidocaine 2% will be injected to ear canal using insulin syringe. Following anesthesia, sharp rosen will be used for trimming of TM perforation margins and gel foams will be put in the middle ear. Then one of the large gel foams will be located in middle ear, under TM, and another one will be fixed in ear canal on the TM. Ear canal will be filled with small gel foams and Tetracycline mesh and wound dressing will be done using one gauze and surgifix. After operation, patients will be visited in recovery room and will be discharged with oral cephalexin. Intervention 2: After transferring the patient to operation room and before presence of surgeon, small (1 and 2- mm) and two large (1 to 2 mm more than size of perforation) gel foams will be prepared  and will be impregnated with normal saline for blinding purpose. Then surgeon, who is not aware of added material to gel foams, will be paged to the OR. After convenient prep and drep 1 ml of Lidocaine 2% will be injected to ear canal using insulin syringe. Following anesthesia, sharp rosen will be used for trimming of TM perforation margins and gel foams will be put in the middle ear. Then one of the large gel foams will be located in middle ear, under TM, and another one will be fixed in ear canal on the TM. Ear canal will be filled with small gel foams and Tetracycline mesh and wound dressing will be done using one gauze and surgifix. After operation, patients will be visited in recovery room and will be discharged with oral cephalexin.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hossein Khosravi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nosrati Alley, Sheykh Bahaei st, Mollasadra st., Vanaq sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8862 0826</telephone>
        <email>dr.mhkhosravi@gmail.com</email>
        <affiliation>Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoumeh Saeedi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nosrati Alley, Sheykh Bahaei st, Mollasadra st., Vanaq sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8862 0826</telephone>
        <email>m.saeedi67@gmail.com</email>
        <affiliation>1-	Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Baqiyatallah Unive</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients with ages between 18 and 60 years old who were candidates for type I Tympanoplasty were enrolled in the study. &#13;
Patients with active otorrhea, cholesteatoma, canal stenosis, TM perforation more than 5 mm, autoimmune and hematologic diseases, active neoplasm, immunosuppressive treatment and diabetes as well as smokers were excluded from the study.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H72</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Perforation of tympanic membrane</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>After transferring the patient to operation room and before presence of surgeon, 8 ml of blood will be obtained from patient’s brachial vein in intervention group and will be stored in PRP kits (RegenKit BCT). Samples will be centrifuged in room’s temperature by 3000 rounds/min in 5 minutes then 3 ml of the resulting solution will be disposed from the top of the kit. Based on factory’s instruction, the remaining solution will be shaken for obtaining 1ml of high density and homogenous PRP.  In the following, small (1 and 2- mm) and two large (1 to 2 mm more than size of perforation) gel foams will be prepared and enriched with PRP in galipot. In control group gel foams will be impregnated with normal saline for blinding purpose. Then surgeon, who is not aware of added material to gel foams, will be paged to the OR. After convenient prep and drep 1 ml of Lidocaine 2% will be injected to ear canal using insulin syringe. Following anesthesia, sharp rosen will be used for trimming of TM perforation margins and gel foams will be put in the middle ear. Then one of the large gel foams will be located in middle ear, under TM, and another one will be fixed in ear canal on the TM. Ear canal will be filled with small gel foams and Tetracycline mesh and wound dressing will be done using one gauze and surgifix. After operation, patients will be visited in recovery room and will be discharged with oral cephalexin.</i_keyword>
      <i_keyword>After transferring the patient to operation room and before presence of surgeon, small (1 and 2- mm) and two large (1 to 2 mm more than size of perforation) gel foams will be prepared  and will be impregnated with normal saline for blinding purpose. Then surgeon, who is not aware of added material to gel foams, will be paged to the OR. After convenient prep and drep 1 ml of Lidocaine 2% will be injected to ear canal using insulin syringe. Following anesthesia, sharp rosen will be used for trimming of TM perforation margins and gel foams will be put in the middle ear. Then one of the large gel foams will be located in middle ear, under TM, and another one will be fixed in ear canal on the TM. Ear canal will be filled with small gel foams and Tetracycline mesh and wound dressing will be done using one gauze and surgifix. After operation, patients will be visited in recovery room and will be discharged with oral cephalexin.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Healing of Tympanic Membrane. Timepoint: 2 and 3 months after intervention. Method of measurement: Hook tool.</prim_outcome>
      <prim_outcome>Tympanic Membrane Rupture. Timepoint: Before Intervention. Method of measurement: Hook tool.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Side Effects. Timepoint: 2 and 3 months after intervention. Method of measurement: History and Examination.</sec_outcome>
      <sec_outcome>Treatment Cost. Timepoint: After Intervention. Method of measurement: Receipt.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Baqiyatallah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-10-26</approval_date>
        <contact_name>Baqiyatallah University of Medical Sciences</contact_name>
        <contact_address>Nosrati Alley, Sheykh Bahaei Street, Mollasadra street, Vanaq Square, Tehran, Iran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
